Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On Hematology in Huntington Beach to present "Initial Results of the Phase 2 Treatment Naive Cohor... Author: moasc Added: 02/01/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts